Published in N Engl J Med on November 03, 1988
Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev (1998) 5.36
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest (1990) 2.96
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1993) 2.26
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun (1991) 1.97
Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun (2000) 1.73
Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits. Hum Vaccin (2008) 1.67
In utero exposure to helminth and mycobacterial antigens generates cytokine responses similar to that observed in adults. J Clin Invest (1997) 1.64
Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. Infect Immun (1992) 1.58
Early-onset neonatal sepsis. Clin Microbiol Rev (2014) 1.53
Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1994) 1.53
Inactivation of the alpha C protein antigen gene, bca, by a novel shuttle/suicide vector results in attenuation of virulence and immunity in group B Streptococcus. Proc Natl Acad Sci U S A (1997) 1.43
Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun (1990) 1.43
Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun (2002) 1.42
Group B streptococcus. Is it time for a screening program? Can Fam Physician (1995) 1.37
Group B streptococci persist inside macrophages. Immunology (1998) 1.36
Antigen-specific immune responses to influenza vaccine in utero. J Clin Invest (2007) 1.36
Group B streptococcal conjugate vaccines. Arch Dis Child (2003) 1.32
Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1992) 1.27
A protective surface protein from type V group B streptococci shares N-terminal sequence homology with the alpha C protein. Infect Immun (1996) 1.27
Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest (1994) 1.19
Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule. Infect Immun (1998) 1.19
Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun (1999) 1.15
Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model. Infect Immun (1998) 1.12
Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect Immun (1999) 1.12
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun (2002) 1.08
Neonatal meningitis in England and Wales: a review of routine national data. Arch Dis Child (1994) 1.04
Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent. Infect Immun (1998) 1.03
Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun (2002) 0.99
Neonatal sepsis and neutrophil insufficiencies. Int Rev Immunol (2010) 0.96
Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci. Infect Immun (2002) 0.94
Murine monoclonal antibodies to type Ib polysaccharide of group B streptococci bind to human milk oligosaccharides. Infect Immun (1992) 0.92
Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons. Infect Immun (1996) 0.91
Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein. Clin Vaccine Immunol (2008) 0.91
Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun (2007) 0.90
Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection. Infect Immun (2004) 0.87
Group B Streptococcus vaccine: state of the art. Ther Adv Vaccines (2015) 0.86
Phylogenetic lineage and pilus protein Spb1/SAN1518 affect opsonin-independent phagocytosis and intracellular survival of Group B Streptococcus. Microbes Infect (2011) 0.85
Genomic analysis reveals the molecular basis for capsule loss in the group B Streptococcus population. PLoS One (2015) 0.85
The prevention of early-onset group B streptococcal infections in the newborn. Can J Infect Dis (1994) 0.83
Maternal immunity and antibody response of neonatal mice to pneumococcal type 19F polysaccharide. J Clin Microbiol (1991) 0.83
Pooled protein immunization for identification of cell surface antigens in Streptococcus sanguinis. PLoS One (2010) 0.82
Identification and immunoreactivity of proteins released from Streptococcus agalactiae. Eur J Clin Microbiol Infect Dis (2004) 0.82
Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate. Infect Immun (1994) 0.80
Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine. Infect Immun (2016) 0.78
Fine specificity and cross-reactions of monoclonal antibodies to group B streptococcal capsular polysaccharide type III. Vaccine (2012) 0.78
A systematic review of ethical issues in vaccine studies involving pregnant women. Hum Vaccin Immunother (2016) 0.76
Peripartum transmission of penicillin-resistant Streptococcus pneumoniae. J Clin Microbiol (2003) 0.75
Group B streptococcal vaccine in pregnant women. N Engl J Med (1989) 0.75
Transmission probabilities and durations of immunity for three pathogenic group B Streptococcus serotypes. Infect Genet Evol (2011) 0.75
Control of neonatal group B streptococcal infection. J R Soc Med (1993) 0.75
Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization. Vaccine (2017) 0.75
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000Res (2016) 0.75
Helminth infection during pregnancy: insights from evolutionary ecology. Int J Womens Health (2016) 0.75
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA (1998) 4.94
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol (1973) 4.49
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Continuous and discontinuous protein antigenic determinants. Nature (1986) 3.26
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J Infect Dis (1976) 3.20
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest (1990) 2.96
Bacteroides fragilis subspecies in clinical isolates. Ann Intern Med (1977) 2.95
Structural features of polysaccharides that induce intra-abdominal abscesses. Science (1993) 2.86
Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature (2001) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci U S A (1992) 2.65
Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med (1976) 2.55
Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis (1999) 2.50
Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J Infect Dis (1973) 2.47
Characterization of gonococcal antigens responsible for induction of bactericidal antibody in disseminated infection. J Clin Invest (1977) 2.46
Chemical and biological characterization of the lipopolysaccharide of Bacteroides fragilis subspecies fragilis. J Infect Dis (1976) 2.45
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Immunochemical characterization of the outer membrane complex of Bacteroides fragilis subspecies fragilis. J Infect Dis (1975) 2.39
Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun (1976) 2.38
Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem (1987) 2.35
Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A (1996) 2.34
Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem (2001) 2.30
In whose best interest? Breaching the academic-industrial wall. N Engl J Med (2000) 2.28
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1993) 2.26
Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest (1977) 2.23
Location of 'continuous' antigenic determinants in the protruding regions of proteins. EMBO J (1986) 2.22
Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry (1981) 2.17
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A (1989) 2.13
Changing epidemiology of group B streptococcal colonization. Pediatrics (1999) 2.09
A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect Immun (1991) 2.06
Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med (1979) 2.06
A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol (2010) 2.02
The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem (1992) 2.00
Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry (1992) 1.98
Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun (1991) 1.97
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infect Immun (1991) 1.95
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
The changing spectrum of group B streptococcal disease. N Engl J Med (1993) 1.94
Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest (1995) 1.91
International, collaborative experience of 1789 patients having multifetal pregnancy reduction: a plateauing of risks and outcomes. J Soc Gynecol Investig (1996) 1.87
Surgical treatment of syringomyelia. Favorable results with syringoperitoneal shunting. J Neurosurg (1984) 1.84
Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics (1981) 1.83
Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem (1980) 1.83
Neonatal mouse model of group B streptococcal infection. J Infect Dis (1992) 1.82
Skull base and calvarial deformities: association with intracranial changes in craniofacial syndromes. AJNR Am J Neuroradiol (1996) 1.81
Mouse protection test for group B Streptococcus type III. J Infect Dis (1979) 1.80
Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis (2000) 1.79
Recurrent meningitis and Mondini dysplasia. Arch Otolaryngol Head Neck Surg (1990) 1.77
Group B streptococcal vaccines. Rev Infect Dis (1985) 1.74
Isolation and identification of encapsulated strains of Bacteroides fragilis. J Infect Dis (1977) 1.74
Revised classification of posterior fossa cysts and cystlike malformations based on the results of multiplanar MR imaging. AJR Am J Roentgenol (1989) 1.74
Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis (1979) 1.71
Bactericidal antibody and susceptibility to otitis media caused by nontypable strains of Haemophilus influenzae. J Pediatr (1980) 1.69
Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. J Neurosurg (1994) 1.68
Phenotypic diversity in the alpha C protein of group B streptococci. Infect Immun (1991) 1.64
NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives. Biochemistry (1997) 1.63
Cellular immunity to Bacteroides fragilis capsular polysaccharide. J Exp Med (1982) 1.62
Iron deficiency and glycosylated haemoglobin A. Lancet (1980) 1.62
Interventional neuroradiological management of vein of Galen malformations in the neonate. Neurosurgery (1990) 1.62
Rapid diagnosis of type III group B streptococcal meningitis by latex particle agglutination. J Pediatr (1979) 1.61
Characterization of serum resistance of Neisseria gonorrhoeae that disseminate. Roles of blocking antibody and gonococcal outer membrane proteins. J Clin Invest (1982) 1.60
Fetal blood sampling demonstrating chimerism in monozygotic twins discordant for sex and tissue karyotype (46,XY and 45,X) Prenat Diagn (1990) 1.60
Sonographic estimation of fetal weight. The value of femur length in addition to head and abdomen measurements. Radiology (1984) 1.60
Polysaccharide biosynthesis locus required for virulence of Bacteroides fragilis. Infect Immun (2001) 1.59
Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med (1987) 1.59
Purification and immunochemical characterization of the outer membrane complex of Bacteroides melaninogenicus subspecies asaccharolyticus. J Infect Dis (1977) 1.59
Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. Infect Immun (1992) 1.58
Bactericidal antibody assay using 14 C-labeled Neisseria meningitidis. Proc Soc Exp Biol Med (1972) 1.57
Bacterial capsule--old dogmas and new tricks. J Infect Dis (1986) 1.57
Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age. Surg Gynecol Obstet (1993) 1.57
T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem (2000) 1.57
Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to Bacteroides fragilis. J Immunol (1986) 1.57
Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates. N Engl J Med (1992) 1.57
Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Infect Immun (1999) 1.57
Evidence for T cell-dependent immunity to Bacteroides fragilis in an intraabdominal abscess model. J Clin Invest (1982) 1.56
Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus. Biochemistry (1983) 1.54
Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg (2001) 1.53
A 5-year review of recurrent group B streptococcal disease: lessons from twin infants. Clin Infect Dis (2000) 1.53
Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1994) 1.53
Natural serum bactericidal activity against Neisseria gonorrhoeae isolates from disseminated, locally invasive, and uncomplicated disease. J Immunol (1980) 1.52
Unusual occurrence of an epidemic of type Ib/c group B streptococcal sepsis in a neonatal intensive care unit. J Infect Dis (1987) 1.51
Progression of multiple cryptic vascular malformations associated with anomalous venous drainage. Case report. J Neurosurg (1994) 1.50
Improvement in outcomes of multifetal pregnancy reduction with increased experience. Am J Obstet Gynecol (2001) 1.50
Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr (1985) 1.49
Commercial latex agglutination for detection of group B streptococcal antigen in body fluids. J Pediatr (1983) 1.47
Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. J Clin Invest (1982) 1.47